pd 169316 has been researched along with Ovarian Neoplasms in 1 studies
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, Y | 1 |
| O'Connor, LM | 1 |
| Shepherd, TG | 1 |
| Nachtigal, MW | 1 |
1 other study available for pd 169316 and Ovarian Neoplasms
| Article | Year |
|---|---|
The p38 MAPK inhibitor, PD169316, inhibits transforming growth factor beta-induced Smad signaling in human ovarian cancer cells.
Topics: Activins; Cell Line, Tumor; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitor | 2003 |